Lucid, Inc. Appoints Martin C. Mihm, Jr., MD, FACP as Chair of Scientific Advisory Board

World-recognized medical professionals will assist Lucid in continuing to develop confocal imaging products and tele-pathology service.

Rochester, NY (PRWEB) June 22, 2010 -- Lucid, Inc., which designs, builds and sells VivaScope® confocal imagers, the only FDA approved non-invasive confocal imagers available to assess skin cancer, today announced the formation of the Scientific Advisory Board (SAB), with the appointment at Martin C. Mihm, Jr., MD, FACP as Advisory Board Chair. The SAB will be made up of world class medical experts to help collaborate with Lucid on the development and advancement of the company’s future in vivo confocal imagers.

“I am honored to chair the Advisory Board and I look forward to working with the company as they continue to develop their technology and their tele-pathology model,” said Dr. Mihm. “I am very impressed with the VivaScope®, the technology has the potential to significantly improve the way we care for our patients.”

Dr. Mihm was a co-founder of the Pigmented Lesion Clinic at Massachusetts General Hospital in Boston, and was co-chairman of the Melanoma Pathology Program of the World Health Organization (WHO) for over twenty years. He also was co-founder and co-director of the Rare Tumor Institute founded by the WHO. He is currently the co-director of the Melanoma Pathology Program of the European Organization for the Research and Treatment of Cancer (EORTC). Dr. Mihm is an internationally recognized expert and consultant for pigmented lesions, lymphoma and cutaneous inflammatory diseases, with expertise covering problematic lesions of lymphoma, and problems relating to inflammatory diseases of the skin. He has co-authored numerous articles and several books concerning skin pathology. Beginning July 1, 2010, Dr. Mihm will transition to Brigham and Women’s Hospital in Boston, making Lucid’s confocal imaging technology available for skin cancer screening and confocal image interpretation services available at the Dana-Farber/Brigham and Women’s Cancer Center.

“Lucid has more than 200 published articles and new studies being published everyday on the effectiveness of the confocal imaging of skin cancers. We are excited to begin formalizing relationships that we have cultivated over the years, beginning with Dr. Mihm as the chair of our Advisory Board,” said Jay Eastman, CEO of Lucid. “I am delighted to have the opportunity to formally work with Dr. Mihm and I am thrilled that he will help us in our mission of refining our products and services, both for skin cancer and a number of other clinical applications where confocal imaging can save not only scars, but save lives through earlier detection.”

Lucid’s VivaScope® series of reflectance microscopes provide images of living skin at cellular resolution. VivaScope® confocal images can be transferred online to dermatopathologists through Lucid’s VivaNet® to substantially reduce the time required for image interpretation and reporting by these specialists.

About Lucid, Inc.
Lucid, Inc., based in Rochester, NY (USA) is a medical device and information company with offices in North America, Europe, and Australia. Lucid is dedicated to providing improved care for dermatology patients by coupling its noninvasive VivaScope® cellular imaging technology with its innovative VivaNet® medical information system to allow secure, HIPAA compliant, near real-time collaboration between dermatologists and other medical specialists. The VivaScope® system provides rapid online medical image transfer storage and retrieval, thus enabling these critical collaborative consultations. The technologies delivered by Lucid provide
images that physicians use in forming critical clinical judgments in cases of dermatological disease while ensuring patient comfort and piece of mind. Find the company online at http://www.lucid-tech.com. VivaNet® and VivaScope® are registered trademarks of Lucid, Inc.

# # #
Contact Information
Megan Rusnak
212-838-3777

Online Web 2.0 Version
You can read the online version of this press release here.